Literature DB >> 31714414

CORR Insights®: PROMIS Function Scores Are Lower in Patients Who Underwent More Aggressive Local Treatment for Desmoid Tumors.

John H Healey1.   

Abstract

Entities:  

Mesh:

Year:  2020        PMID: 31714414      PMCID: PMC7145064          DOI: 10.1097/CORR.0000000000001046

Source DB:  PubMed          Journal:  Clin Orthop Relat Res        ISSN: 0009-921X            Impact factor:   4.755


× No keyword cloud information.
  9 in total

1.  Sorafenib for Advanced and Refractory Desmoid Tumors.

Authors:  Mrinal M Gounder; Michelle R Mahoney; Brian A Van Tine; Vinod Ravi; Steven Attia; Hari A Deshpande; Abha A Gupta; Mohammed M Milhem; Robert M Conry; Sujana Movva; Michael J Pishvaian; Richard F Riedel; Tarek Sabagh; William D Tap; Natally Horvat; Ethan Basch; Lawrence H Schwartz; Robert G Maki; Narasimhan P Agaram; Robert A Lefkowitz; Yousef Mazaheri; Rikiya Yamashita; John J Wright; Amylou C Dueck; Gary K Schwartz
Journal:  N Engl J Med       Date:  2018-12-20       Impact factor: 91.245

2.  PROMIS Function Scores Are Lower in Patients Who Underwent More Aggressive Local Treatment for Desmoid Tumors.

Authors:  Erik T Newman; Jonathan Lans; Jason Kim; Marco Ferrone; John Ready; Joseph Schwab; Kevin Raskin; Santiago Lozano Calderon
Journal:  Clin Orthop Relat Res       Date:  2020-03       Impact factor: 4.176

3.  Near universal detection of alterations in CTNNB1 and Wnt pathway regulators in desmoid-type fibromatosis by whole-exome sequencing and genomic analysis.

Authors:  Aimee M Crago; Juliann Chmielecki; Mara Rosenberg; Rachael O'Connor; Caitlin Byrne; Fatima G Wilder; Katherine Thorn; Phaedra Agius; Deborah Kuk; Nicholas D Socci; Li-Xuan Qin; Matthew Meyerson; Meera Hameed; Samuel Singer
Journal:  Genes Chromosomes Cancer       Date:  2015-07-14       Impact factor: 5.006

4.  The enigma of desmoid tumors.

Authors:  J J Lewis; P J Boland; D H Leung; J M Woodruff; M F Brennan
Journal:  Ann Surg       Date:  1999-06       Impact factor: 12.969

5.  Aggressive fibromatosis (desmoid tumor) is derived from mesenchymal progenitor cells.

Authors:  Colleen Wu; Saeid Amini-Nik; Saied Nik-Amini; Puviindran Nadesan; William L Stanford; Benjamin A Alman
Journal:  Cancer Res       Date:  2010-09-14       Impact factor: 12.701

6.  A prognostic nomogram for prediction of recurrence in desmoid fibromatosis.

Authors:  Aimeé M Crago; Brian Denton; Sébastien Salas; Armelle Dufresne; James J Mezhir; Meera Hameed; Mithat Gonen; Samuel Singer; Murray F Brennan
Journal:  Ann Surg       Date:  2013-08       Impact factor: 12.969

7.  Indomethacin and ascorbate inhibit desmoid tumors.

Authors:  W R Waddell; R E Gerner
Journal:  J Surg Oncol       Date:  1980       Impact factor: 3.454

8.  Low-dose chemotherapy of desmoid tumors.

Authors:  A J Weiss; R D Lackman
Journal:  Cancer       Date:  1989-09-15       Impact factor: 6.860

9.  A Metabolomics Pilot Study on Desmoid Tumors and Novel Drug Candidates.

Authors:  Kelly A Mercier; Mushriq Al-Jazrawe; Raymond Poon; Zachery Acuff; Benjamin Alman
Journal:  Sci Rep       Date:  2018-01-12       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.